Kyverna Therapeutics, Inc. (KYTX)
KYTXNASDAQ-GSBiotechnology: Biological Products (No Diagnostic Substances)
$5.08
-0.0900 (-1.74%) today
Closed, Nov 10, 4:00 PM ET
- Market cap
- $314.16m
- P/E
- –
- EPS, last 4 quarters
- $-2.94
- Dividend yield
- –
- Day range
- –
- 52-week range
- $4.50 to $13.67
- Average volume
- 895.8k
- Previous close
- $5.17
Analysts
4 coveringBuy4 buy, 0 hold, 0 sell
Targets a year out average $30.33, +497.0% from here
Earnings
next estimate $-0.6800Next report Nov 11, 2026
Sep 2025
+12.4%
Dec 2025
0.0%
Mar 2026
+12.0%
Jun 2026
+6.0%
estimate reported, and the surprise
Financials
| Quarter | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | – | – | – | – |
| Gross profit | – | – | – | – |
| Operating income | -$38.73m | -$39.28m | -$41.37m | -$39.56m |
| Net income | -$36.79m | -$37.80m | -$39.73m | -$38.32m |
News
8 latest- Oversold Conditions For Kyverna Therapeutics (KYTX)BNK Invest · Oct 26, 2026
- Kyverna's Miv-cel Shows 49% Walking Improvement At One Year; Stock Down RTTNews · Oct 21, 2026
- Kyverna's CAR T Therapy Shows Durable Results In Stiff Person Syndrome RTTNews · Oct 21, 2026
- One-Year Benefits Sustain Momentum For Kyverna's Autoimmune CAR-T Therapy; Stock Up RTTNews · Sep 24, 2026
- Cue Biopharma Appoints Dominic Borie As CMO RTTNews · Jul 13, 2026
- Kyverna Therapeutics vs. Vertex Pharmaceuticals: Which Drug Developer Stock Is a Better Buy in 2026?The Motley Fool · Jun 8, 2026
- Kyverna Reports Positive Phase 1 COMPARE Data For Miv-cel In Treating Rheumatoid Arthritis RTTNews · Jun 4, 2026
- Kyverna Therapeutics Names Greg Martini CFO RTTNews · May 18, 2026
The company
Kyverna Therapeutics, Inc. (Nasdaq: KYTX) is a late-stage clinical immunology company pioneering differentiated therapies with curative potential for neurologic autoimmune diseases. Kyverna's lead autologous CD19-targeting CAR T-cell therapy candidate, miv-cel (mivocabtagene autoleucel, KYV-101), has demonstrated the potential to fundamentally change the treatment paradigm across multiple B-cell-driven autoimmune diseases. Kyverna is advancing its potentially first-in-class neuroimmunology franchise with its recently completed registrational trial in stiff person syndrome (SPS) and an ongoing registrational trial for generalized myasthenia gravis (gMG). Miv-cel has received three FDA Regenerative Medicine Advanced Therapy (RMAT) designations, in SPS, gMG, and non-active secondary progressive multiple sclerosis (naSPMS) based on compelling clinical data and significant unmet need, further reinforcing the therapy's potential across neuroimmunology.
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ-GS
- Region
- North America
- Website
- kyvernatx.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.